Shopping Cart
- Remove All
Your shopping cart is currently empty
p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $1,168 | 8-10 weeks |
| Description | p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, long duration, and low clearance, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production. |
| Targets&IC50 | p38 MAPK:68 nM |
| In vivo | Methods: p38 MAPK-IN-1 (1 mg/kg, intravenous injection and; 10 mg/kg, oral administration) was administered to male wistar rats for in vivo pharmacokinetic study. Results: p38 MAPK-IN-1 had a t1/2 of 7.4 hours and an intravenous CL of 2.7 mL/min/kg. The Cmax of p38 MAPK-IN-1 in male wistar rats after oral administration was 5.3 μM. [1] |
| Molecular Weight | 348.35 |
| Formula | C21H14F2N2O |
| Cas No. | 1006378-90-0 |
| Smiles | O=N=1C=CC=2C(=NC=CC2C=3C=CC(F)=CC3F)C1C=4C=CC=CC4C |
| Relative Density. | 1.27 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (57.41 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.